{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'REFERENCES', '1.', 'Patel A, Jernigan DB, nCo VCDCRT. Initial Public Health Response and Interim Clinical', 'Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31,', '2019-February 4, 2020. MMWR Morb Mortal Wkly Rep 2020;69(5):140-146. DOI:', '10.15585/mmwr.mm6905e1.', '2.', \"Organization WH. WHO Director-General's opening remarks at the media briefing on\", 'COVID-19-11 March 2020. Geneva, Switzerland2020.', '3.', 'COVID Data Tracker. Centers for Disease Control and Prevention.', '(https://covid.cdc.gov/covid-data-tracker/).', '4.', 'Prevention CfDCa. SARS-CoV-2 Variant Classifications and Definitions.', '5.', 'Prevention CfDCa. People with Certain Medical Conditions.', '(https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-', 'medical-', 'conditions.html?CDC AA refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2', '019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.html).', '6.', 'Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999;17', 'Suppl 1:S3-10. DOI: 10.1016/s0264-410x(99)00099-7.', '7.', 'Glezen WP. Serious morbidity and mortality associated with influenza epidemics.', 'Epidemiol Rev 1982;4:25-44. DOI: 10.1093/oxfordjournals.epirev.a03625', '8.', 'Lisa A. Grohskopf EA, Karen R. Broder, Lenee H. Blanton, Alicia M. Fry, Daniel B.', 'Jernigan, Robert L. Atmar. Prevention and Control of Seasonal Influenza with Vaccines:', 'Recommendations of the Advisory Committee on Immunization Practices - United', 'States, 2020-21 Influenza Season. Centers for Disease Control and Prevention.', '(https://www.cdc.gov/mmwr/volumes/69/rr/rr6908a1.htm?s cid=rr6908a1 w).', '9.', 'Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in', 'the United States. JAMA 2004;292(11):1333-40.DOI: 10.1001/jama.292.11.1333', '10.', 'Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and', 'respiratory syncytial virus in the United States. JAMA 2003;289(2):179-86. DOI:', '10.1001/jama.289.2.179.', '11.', 'Ozaras R, Cirpin R, Duran A, et al. Influenza and COVID-19 coinfection: Report of six', 'cases and review of the literature. J Med Virol 2020;92(11):2657-266 DOI:', '10.1002/jmv.26125', '12.', 'ClinicalTrials.gov. Bethesda, MD: National Library of Medicine; 2021.', '13.', 'COVID-19 Vaccines Food and Drug Administration (https://www.fda.gov/emergency-', 'preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines).', '14.', 'Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA', 'Covid-19 Vaccine. N Engl J Med 2020;383(27):2603-2615.DC', '10.1056/NEJMoa2034577.', '15.', 'Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-', 'CoV-2 Vaccine. N Engl J Med 2021;384(5):403-416. DOI: 10.1056/NEJMoa2035389.', '16.', 'Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in', 'the United States. Center for Disease Control and Prevention.', '(https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-', 'us.html).', '17.', 'COVID-19 ACIP Vaccine Recommendations. Centers for Disease Control and', 'Prevention. (https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html).', '55']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', '18.', 'Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain', 'Immunocompromised Individuals. FDA. (https://www.fda.gov/news-events/press-', ' announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-', 'certain-immunocompromised)', '19.', 'Prevention CfDCa. COVID-19 Vaccine Booster Shot Centers for Disease Control and', 'Prevention. (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html).', '20.', 'Prevention CfDCa. Joint Statement from HHS Public Health and Medical Experts on', 'COVID-19 Booster Shots (https://www.cdc.gov/media/releases/2021/s0818-covid-19-', 'booster-shots.html)', '21.', 'Administration FaD. FDA Briefing Document: Pfizer-BioNTech COVID-19 Vaccine.', 'Vaccine and Related Biological Products Advisory Committee Meeting2020', '22.', 'Administration FaD. FDA Briefing Document: Moderna COVID-19 Vaccine. Vaccine and', 'Releated Biological Products Advisory Committee Meeting2020.', '23.', 'Frenck RW, Jr., Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the', 'BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med 2021. DOI:', '10.1056/NEJMoa2107456.', '24.', 'Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA', 'COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA', '2021;325(11):1101-110: DOI: 0.1001/jama.2021. 1967.', '25.', 'Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to', 'Prevent Coronavirus Disease 2019 (COVID-19). Fact Sheet for Healthcare Providers', 'Administering /accine(Vaccination Providers) U.S. Food and Drug Administration, 2021.', '(https://www.fda.gov/media/144413/download).', '26.', 'Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to Prevent', 'Coronavirus Disease 2019 (COVID-19). Fact Sheet for Healthcare Providers', 'Administering Vaccine (Vaccination Providers). U.S. Food and Drug Administration', '(FDA), 2021. (https://www.fda.gov/media/144637/download).', '27.', 'Clinical Considerations: Myocarditis and Pericarditis after Receipt of mRNA COVID-19', 'Vaccines Among Adolescents and Young Adults. Centers for Disease Control and', 'Prevention. (https://www.cdc.gov/vaccines/covid-19/clinical-', 'considerations/myocarditis.html)', '28.', 'Comirnaty (COVID-19 Vaccine, mRNA) Evaluation of a Booster Dose (Third Dose) In:', 'Committee VaRBPA, ed.: Food and Drug Administration; 2021:1-39.', '29.', 'Lisa A. Grohskopf EA, Karen R. Broder, Lenee H. Blanton, Alicia M. Fry, Daniel B.', 'Jernigan, Robert L. Atmar. Prevention and Control of Seasonal Influenza with Vaccines:', 'Recommendations of the Advisory Committee on Immunization Practices - United', 'States, 2020-21 Influenza Season. Recommendations and Reports Centers for Disease', 'Control and Prevention, 2021. https://www.cdc.gov/mmwr/volumes/69/rr/rr6908a1.htm', '30.', 'Influenza(Flu) Vaccine (Inactivated or Recombinanat): What you need to know. Vaccine', 'Information Sheet. Centers for Disease Control and Prevention, 2019.', ' (https://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.html)', '31.', 'Prevention CfDCa. Interim Clinical Considerations for Use of COVID-19 Vaccines', 'Currently Authorized in the United States', 'alert icon. (https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html).', '32.', 'COVID-19 Vaccine Emergency Use Authorization (EUA) Fact Sheets for Recipients and', 'Caregivers. Centers for Disease Control and Prevention.', 'https://www.cdc.gov/vaccines/covid-19/eua/index.html)', '56']\n\n###\n\n", "completion": "END"}